Tarsus Raised XDEMVY Sales Guide to $685M-$705M-Now It Has to Prove Alkeus Is a Leap, Not a Distraction

XDEMVY momentum is now the main story

This is the quarter that can force a re-rating. XDEMVY posted $173.9 million in Q2 net product sales, a more than 69% year-over-year increase, and Tarsus responded by lifting full-year 2026 guidance to $685 million to $705 million. Add a Q1 base of more than $145 million in XDEMVY sales, and the core business is becoming harder to value as anything less than a fast-scaling franchise. In that setup, investors can start separating today's commercial engine from tomorrow's pipeline optionality.

The near-term bull case is straightforward: XDEMVY momentum is real, and Alkeus adds a Phase 3 program in Stargardt disease. The counterargument is that Tarsus is about to get louder, not necessarily better, as it manages a commercial ramp and M&A integration at the same time. The question now is whether the market keeps paying primarily for XDEMVY execution or starts pricing in a broader growth platform.

The quarterly slope still looks constructive

XDEMVY went from more than $145 million in XDEMVY sales in Q1 to $173.9 million in Q2 net product sales, and management raised the full-year target to $685 million to $705 million. That does not look like a maturing curve; it looks like a business that is still building commercial traction.

Watchpoint:Calliope topline data expected in the first half of 2027 is the key signpost. If XDEMVY continues compounding while that pipeline catalyst arrives, investors may be willing to support a more ambitious view of the company. If Alkeus dominates the story first, the market will expect a similar level of proof.

XDEMVY still has room beyond current guidance

The guidance raise is the headline, but the larger point is the gap between where XDEMVY is today and where management says it can go.

The sales runway is still wide

Full-year 2025 XDEMVY net product sales already reached $451.4 million, up more than 150% year-over-year, and management still sees a potential path to peak sales exceeding $2 billion. That leaves a lot of distance between current performance and the long-term ceiling.

The growth also does not look dependent on simply adding new prescribers. Tarsus said nearly half of core eye care professionals are prescribing XDEMVY weekly, which suggests the product is moving from trial to routine care. In specialty eye care, that kind of deeper utilization can matter as much as initial awareness.

Why the upside case stays alive

If prescribing frequency and patient demand keep improving, current guidance can start to look more like a conservative base case than a ceiling. That would make XDEMVY less of a one-quarter story and more of a platform for future upside.